Wall Street Analysts Are Bullish on Top Healthcare Picks

Theres a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Agilent (AResearch Report), Immatics (IMTXResearch Report) and Kinnate Biopharma (KNTEResearch Report) with bullish sentiments. Agilent (A) In a report issued on October 12, Puneet Souda from SVB Securities maintained a Buy rating on Agilent, with a price target of $145.00. The companys shares closed last Thursday at $127.90.

According to TipRanks.com, Souda is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -13.7% and a 31.5% success rate. Souda covers the Healthcare sector, focusing on stocks such as AbCellera Biologics, Castle Biosciences, and Twist Bioscience.

Agilent has an analyst consensus of Strong Buy, with a price target consensus of $152.78.

See today’s best-performing stocks on TipRanks >> Immatics (IMTX) In a report released yesterday, Jonathan Chang from SVB Securities reiterated a Buy rating on Immatics. The companys shares closed last Thursday at $11.29.

According to TipRanks.com, Chang s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -15.7% and a 24.9% success rate. Chang covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Karyopharm Therapeutics, and Bicycle Therapeutics.

Immatics has an analyst consensus of Moderate Buy, with a price target consensus of $28.00, implying a 154.5% upside from current levels. In a report issued on October 10, Chardan Capital also maintained a Buy rating on the stock with a $28.00 price target.

Kinnate Biopharma (KNTE) SVB Securities analyst Andrew Berens maintained a Buy rating on Kinnate Biopharma on October 12. The companys shares closed last Thursday at $8.37, close to its 52-week low of $5.75.

According to TipRanks.com, Berens is a 1-star analyst with an average return of -0.9% and a 43.6% success rate. Berens covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Deciphera Pharmaceuticals, and Zentalis Pharmaceuticals.

Currently, the analyst consensus on Kinnate Biopharma is a Strong Buy with an average price target of $36.33, implying a 369.4% upside from current levels. In a report issued on October 11, Jefferies also maintained a Buy rating on the stock with a $46.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. Read More on A:

Leave a Reply

Your email address will not be published. Required fields are marked *